David Ian Bell

David Ian Bell currently works at Biomat USA, Inc., as Chief Executive Officer, Grifols Innovation & New Technologies Ltd., as President & Chief Executive Officer, Grifols Bio Supplies, Inc., as Chief Executive Officer, Singulex, Inc., as Director, Alkahest, Inc., as President & Director, Plasma Protein Therapeutics Association, as Director from 2020, BPC Plasma, Inc., as Director, Theriva Biologics SL, as Director, GigaGen, Inc., as Director, Grifols SA, as Chief Corporate Affairs & Legal Officer, Biotest GmbH & Co. KGaA, as Member-Supervisory Board from 2022, and Grifols USA, Inc., as Vice President-Corporate Operations & Development from 2013.
Dr. Bell also formerly worked at Aradigm Corp., as Director from 2013 to 2018, Shanghai RAAS Blood Products Co., Ltd., as Director, Grifols, Inc., as Vice President-Operations & Development, California State Bar Association, as Member, Alpha Therapeutic Corp., as Secretary, Vice President & General Counsel from 2000 to 2003, and Knapp, Petersen & Clarke PC, as Partner from 1981 to 2000.
Dr. Bell received his undergraduate degree in 1975 from the University of California, Irvine and graduate degree in 1978 from Southwestern Law School.